FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
Authors:
- 22 October 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 25 (2) , e328-e334
Abstract
On May 24, 2019, the Food and Drug Administration approved ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in adult and pediatric patients 12 years and older. Approval was based on Study INCB 18424-271 (REACH-1; NCT02953678), an open-label, single-arm, multicenter trial that included 49 patients with grades 2–4 SR-aGVHD occurring after allogeneic hematopoietic stem cell transplantation. Ruxolitinib was administered at 5 mg twice daily, with dose increases to 10 mg twice daily permitted after 3 days in the absence of toxicity. The Day-28 overall response rate was 57.1% (95% confidence interval [CI]: 42.2–71.2). The median duration of response was 0.5 months (95% CI: 0.3–2.7), and the median time from Day-28 response to either death or need for new therapy for acute GVHD was 5.7 months (95% CI: 2.2 to not estimable). Common adverse reactions included anemia, thrombocytopenia, neutropenia, infections, edema, bleeding, and elevated transaminases. Ruxolitinib is the first drug approved for treatment of SR-aGVHD.Keywords
This publication has 27 references indexed in Scilit:
- International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumTransplantation and Cellular Therapy, 2016
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyLeukemia, 2015
- Activity of therapeutic JAK 1/2 blockade in graft-versus-host diseaseBlood, 2014
- First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow TransplantationTransplantation and Cellular Therapy, 2012
- Response as an end point in treatment trials for acute GVHDBone Marrow Transplantation, 2012
- Risk factors for acute GVHD and survival after hematopoietic cell transplantationBlood, 2012
- Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint StatementTransplantation and Cellular Therapy, 2009
- How I treat refractory acute GVHDBlood, 2007
- A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host diseaseBlood, 2006
- Immunobiology of acute graft-versus-host diseaseBlood Reviews, 2003